Immune checkpoint inhibitors and endocrinopathies in pediatric brain tumor patients.

ABSTRACT:

Objectives

Immune checkpoint inhibitors (ICIs) are emerging treatment options for children with brain tumors, who are already at risk for developing endocrinopathies due to tumor location and treatment. Endocrine ICI-related adverse effects (irAEs) are common in adults but poorly characterized in the pediatric population. The aims of this study were to determine in pediatric brain tumor patients in a single institution (1) if endocrine surveillance took place before and after ICIs were initiated, and (2) the occurrence of endocrine irAEs.

Methods

This is a retrospective chart review of 22 pediatric brain tumor patients treated with ICIs at Children's Hospital Los Angeles between 2010 and 2022. We analyzed endocrine laboratory results, patient demographics, and treatment cour

SUBMITTER: Westermann CR 

PROVIDER: S-EPMC11832116 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature